Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 67 clinical trials
Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women (ASPAIT)

or metastatic lymph nodes randomized to ovarian function suppression (OFS) plus aromatase inhibitors or OFS plus tamoxifen as adjuvant endocrine therapy, and explore the differences of curative

adjuvant chemotherapy
immunohistochemistry
hormone therapy
aromatase inhibitor
immunostimulant
  • 12 views
  • 23 Feb, 2022
  • 11 locations
Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ

, enrolling high-risk and low-risk clinicopathologic features of DCIS, demonstrated that a benefit of tamoxifen in terms of reducing the IBTR is observed in the BCS alone group but not found in the BCS plus

estrogen
breast cancer
breast-conserving surgery
cancer
carcinoma in situ
  • 13 views
  • 14 Feb, 2022
  • 1 location
Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients

researchers. The trial is designed to evaluate the effectiveness of tamoxifen as adjuvant therapy for ER(ER-α)/PR negative, ER-β positive operable breast cancer patients. 688 female ER(ER-α)/PR negative, ER-β

sentinel node
axillary lymph node dissection
adjuvant therapy
breast-conserving surgery
herceptin
  • 30 views
  • 18 May, 2022
  • 17 locations
Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity (AMEERA-6)

This is a phase III, randomized, double blind, multicenter, 2-arm study evaluating the efficacy and safety of amcenestrant compared with tamoxifen in patients with hormone receptor-positive

her2/neu-positive breast cancer
epidermal growth factor
exemestane
HER2
growth factor
  • 0 views
  • 28 Jun, 2022
  • 3 locations
Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer

breast cancer. Endocrine therapy is the core treatment for this subtype of BC. Tamoxifen, aromatase inhibitor or their sequential administration can reduce the recurrence and mortality of this BC

chemotherapy drugs
hormone therapy
aromatase inhibitor
mastectomy
erbb2
  • 0 views
  • 22 Oct, 2021
  • 1 location
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer (POLAR)

modulator (such as tamoxifen) or an aromatase inhibitor (anastrozole, letrozole, exemestane) or fulvestrant (Faslodex). Premenopausal women and men may also receive a drug called an LHRH (luteinizing

anastrozole
estrogen
gnrh
fulvestrant
cancer
  • 2 views
  • 19 Feb, 2022
  • 55 locations
Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast (ROMANCE)

<0.001). Sixty percent of the patients received tamoxifen in both groups. Several studies showed that the same molecular classes were identified in DCIS as in invasive cancers. Studies

estrogen
human epidermal growth factor
cancer
epidermal growth factor
progesterone
  • 51 views
  • 09 Feb, 2022
  • 27 locations
ExclUsive endocRine Therapy Or Partial Breast Irradiation for Women Aged 70 Years Early Stage Breast Cancer

Rationale and relevance for patients and the scientific community. In low risk early stage patients 70 years, exclusive Partial Breast Irradiation (PBI) as radiation therapy (RT) approach might be superior in terms of Health-Related Quality of Life (HRQoL), when compared to exclusive endocrine therapy (ET) following breast-conserving surgery (BCS). Assuming …

  • 0 views
  • 16 Apr, 2021
  • 1 location
DianaWeb: Before and After Study Online Based Participatory Research on Breast Cancer Women

DianaWeb is a community-based participatory research (CBPR) offered to Italian breast cancer patients. The aim of the study is the evaluation of effectiveness of a lifestyle and nutrition intervention to improve the prognosis. DianaWeb study utilizes an interactive website - http://www.dianaweb.org/ - to monitor patient life-style, and to obtain clinical, …

  • 0 views
  • 07 Oct, 2021
  • 1 location
Efficacy Comparison of Tamoxifen and Tamoxifen With Antioxidants on Semen Quality of Male With Idiopathic Infertility

Objective of the study is to compare the efficacy of tamoxifen alone & tamoxifen with antioxidant on semen quality of infertile male with abnormal parameters (sperm count, motility, vitality

Accepts healthy volunteers
  • 0 views
  • 25 Mar, 2022